Granola bar recall: FDA updates recall for over 2 million MadeGood granola bars
The U.S. Food and Drug Administration has made an update to its MadeGood granola bar recall. The popular granola bars, sold ...
Hosted on MSN8h
Granola bar recall: FDA gives update after snacks possibly contain metal
Check your cupboards and pantries. Riverside Natural Foods is recalling certain batches of MadeGood granola bars.
Blavity on MSN9h
FDA Granola Bar Recall That Impacted Over 2 Million Cases Gets Update
The Food and Drug Administration (FDA) announced that MadeGood granola bars recalled in December have received a Class II ...
WTVO11h
FDA upgrades severity of granola bar recall
The Food and Drug Administration (FDA) is warning consumers to not buy multiple types of granola bars. The bars were upgraded to class 2, which means consuming the granola could cause ...
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million - Following pre-NDA meeting with FDA, on track to submit TransCon CNP ...
FDA's approval of non-opioid pain pill could be game-changer
The Federal Drug Administration last month approved Journavx, a new kind of non-addictive pain medication. Doctors say ...
Healio1d
FDA approves Evrysdi tablets for spinal muscular atrophy
The FDA has approved Evrysdi in tablet form for patients with spinal muscular atrophy aged 2 years and older who weigh more ...
manilatimes1d
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...
manilatimes1d
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
PHILADELPHIA, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is also pleased to announce that its phase 2 clinical study (SKNJCT-003) which is ...
thehealthy2d
RFK Jr.’s New Role Will Likely Change 6 Longstanding FDA Practices, Says National Expert
A seasoned FDA compliance and regulations expert says you can watch for these major ways health intelligence may change for ...
Alnylam: Waiting For Regulatory Updates In March
Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.
JD Supra2d
Say Goodbye to the Red Dye: Legal Implications Following the FDA’s Recent Ban
On January 16, 2025, the U.S. Food and Drug Administration (FDA) announced a significant regulatory change by revoking the authorization for use ...